paraquat has been researched along with vasoactive intestinal peptide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berisha, HI; Foda, HD; Pakbaz, H; Said, SI; Trotz, M | 1 |
| Callahan, LM; Federoff, HJ; Giuliano, RE; Henricksen, LA; Luo, Y; Prifti, L | 1 |
2 other study(ies) available for paraquat and vasoactive intestinal peptide
| Article | Year |
|---|---|
Paraquat-induced lung injury: prevention by vasoactive intestinal peptide and related peptide helodermin.
Topics: Animals; Body Water; Guinea Pigs; In Vitro Techniques; Intercellular Signaling Peptides and Proteins; Lung; Lung Diseases; Male; Paraquat; Peptides; Perfusion; Permeability; Pressure; Prostaglandin-Endoperoxide Synthases; Proteins; Vasoactive Intestinal Peptide | 1993 |
VIP is a transcriptional target of Nurr1 in dopaminergic cells.
Topics: Animals; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Dopamine; Down-Regulation; Gene Expression Regulation, Developmental; Herbicides; Mesencephalon; Mice; Mice, Knockout; Neurons; Nuclear Receptor Subfamily 4, Group A, Member 2; Paraquat; Parkinson Disease; Promoter Regions, Genetic; Regulatory Elements, Transcriptional; RNA, Messenger; Substantia Nigra; Transcription Factors; Transcriptional Activation; Vasoactive Intestinal Peptide | 2007 |